Home > News

Savant Listed on the New OTC Market and selected as a "SRDI" enterprise in Beijing

2022/8/12 16:27:24 Views:273

According to the news on August 8, Beijing Savant Biotechnology Co., ltd. (Stock Code No.: 873748) was listed on the New OTC Market. The operating revenue of the company in 2020 and 2021 is 164 million CNY and 156 million CNY respectively, and the net profit attributable to the parent is 41.5468 million CNY and 17.7089 million CNY respectively.


Beijing Savant Biotechnology Co.,

Booth No. of CACLP 2022: A3-2319 a high-tech enterprise specialized in the research, development, production and sales of in vitro diagnostic reagents and instruments with the business tenet of "leading innovation in technology and product stability". The company has a wide range of products, forming a comprehensive development pattern of chemiluminescent tumor marker series, thyroid function series, POCT calcium deficiency series, anemia series and other products, which can provide a series of solutions for clinical diagnosis. The company's products have been widely used in domestic hospitals at all levels, physical examination centers, third-party medical testing centers and other medical institutions.


Savant has been committed to the field of medical testing for many years. Bearing the concept of "doctors' conscience" in mind, Savant expect to gradually optimize the disease diagnosis path of "early diagnosis, early treatment and early discovery" through high-quality products and services, contributing to the medical burden alleviation for the purpose of public and society, furthermore realizing the grand vision of "healthy China".


Savant adheres to the principle of "customers first, employees second, shareholders third". We would try our best to provide customers with high-quality products and considerate services. Savant would pay our employees back with better life quality and working environment, and also provide our shareholders with proper return.


As of the date of public transfer, the company has obtained 83 authorized patents, including 30 invention patents, 47 utility model patents and 6 design patents. In October 2020, the company was rated as Beijing " SRDI " small and medium-sized enterprise by Beijing Municipal Bureau of Economy and Information Technology. In March 2022, the company was authorized again.